New shot could help patients with severe blistering skin disease ditch steroids
NCT ID NCT07210554
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests an injection called stapokibart for people with moderate to severe bullous pemphigoid, a painful blistering skin condition. The goal is to see if it can help patients stop taking steroids and keep the disease under control for 36 weeks. About 200 adults aged 18 to 90 will participate, receiving either the drug or a placebo.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BULLOUS PEMPHIGOID (BP) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Peking University First Hospital
Beijing, Beijing Municipality, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.